The startup develops AI-powered small molecule drugs that target RNA to treat cancer, rare diseases, and viral infections. Utilizing a closed-loop RNA target discovery platform, the company identifies novel RNA targets to create first-in-class drugs that meet critical clinical needs.
Funding
Funding not disclosed
Founders
Product
Problem
Many diseases, including cancers, rare genetic disorders, and viral infections, are difficult to treat with traditional small molecule drugs due to the lack of well-defined protein targets or the inability to selectively modulate protein function. This limitation necessitates the exploration of alternative therapeutic targets and mechanisms of action.
Solution
This startup is developing a new class of small molecule therapeutics that directly target RNA, offering a novel approach to treating diseases previously considered undruggable. Their proprietary platform leverages artificial intelligence to identify and validate RNA targets that play critical roles in disease pathogenesis. By selectively binding to these RNA targets, the small molecule drugs can modulate gene expression, disrupt disease-causing pathways, and ultimately provide therapeutic benefit. This approach allows for the development of first-in-class drugs that address unmet clinical needs in oncology, rare diseases, and infectious diseases.
Target Audience
The primary target audience includes pharmaceutical companies seeking innovative drug candidates, as well as patients suffering from cancers, rare genetic disorders, and viral infections with limited treatment options.
Features
- AI-powered RNA target discovery platform for identifying novel therapeutic targets
- Closed-loop system integrating computational modeling, high-throughput screening, and chemical optimization
- Small molecule drug design targeting specific RNA sequences and structures
- Selective modulation of gene expression through RNA targeting
- Development of first-in-class drugs for cancer, rare diseases, and viral infections